Share this article on:

Incretin hormone glucagon-like peptide-1 is increased in patients with acute-phase ST-elevation myocardial infarction treated with a primary percutaneous coronary intervention: a pilot study

Blatt, Alexa,*; Shiloah, Elib,*; Mincha, Sa’ara; Bloch, Olgac; Rapoport, Micha J.b,c

doi: 10.1097/XCE.0000000000000011
Original articles

Objectives The incretin hormone glucagon-like peptide 1 (GLP-1) is assumed to have a cardioprotective effect. It is not known whether GLP-1 levels are increased in patients with acute myocardial infarction. We investigated the GLP-1 levels in patients presenting with ST-segment elevation myocardial infarction (STEMI).

Patients and methods GLP-1 serum level samples were obtained in 12 consecutive patients presenting with acute STEMI before and 24, 72 h, and 90 days after a percutaneous coronary intervention (PCI).

Results The mean GLP-1 levels increased significantly within 24 h after PCI from 27±7.1 to 39.5±11.4 (P<0.04) and reverted to preadmission levels after 3 months. No correlation was found between GLP-1 levels and any of the clinical and laboratory parameters or indicators of myocardial infarction severity. However, both hypertension and smoking history (former and current) were associated with significantly lower GLP-1 levels as compared with normotensive and nonsmoker patients (P<0.01 and P<0.04, respectively).

Conclusion A transient and significant increase in GLP-1 levels occurs in patients after STEMI treated with primary PCI. These pilot data may suggest a role for GLP-1 in the physiologic response to acute ischemic heart disease.

aDivision of Cardiology

bDepartment of Internal Medicine

cDiabetes Laboratory, Sackler Medical School, Assaf Harofeh Medical Center, Tel-Aviv University, Zerifin, Israel

*Alex Blatt and Eli Shiloah contributed equally to the writing of the article.

Correspondence to Micha J. Rapoport, MD, Diabetes and Endocrinology Unit, Sackler Medical School, Assaf Harofeh Medical Center, Tel-Aviv University, Zerifin 70300, Israel Tel: +972 8 9779283; fax: +972 8 9779285; e-mail:

Received April 26, 2013

Accepted June 5, 2013

© 2013Wolters Kluwer Health Lippincott Williams Wilkins